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Background: The main role of the cell cycle is to enable error-free DNA replication, 
chromosome segregation and cytokinesis. One of the best characterised checkpoint 
pathways is the spindle assembly checkpoint, which prevents anaphase onset until the 
appropriate attachment and tension across kinetochores is achieved. MPS1 kinase activity 
is essential for the activation of the spindle assembly checkpoint and has been shown to 
be deregulated in human tumours with chromosomal instability and aneuploidy. Therefore, 
MPS1 inhibition represents an attractive strategy to target cancers. 
Methods: To evaluate CCT271850 cellular potency two specific antibodies that recognise 
the activation sites of MPS1 were used and its anti-proliferative activity was determined in 
91 human cancer cell lines. DLD1 cells with induced GFP-MPS1 and HCT116 cells were 
used in in vivo studies to directly measure MPS1 inhibition and efficacy of CCT271850 
treatment. 
Results: CCT271850 selectively and potently inhibits MPS1 kinase activity in biochemical 
and cellular assays and in in vivo models. Mechanistically, tumour cells treated with 
CCT271850 acquire aberrant numbers of chromosomes and the majority of cells divide 
their chromosomes without proper alignment due to abrogation of the mitotic checkpoint, 
leading to cell death. We demonstrated a moderate level of efficacy of CCT271850 as a 
single agent in a human colorectal carcinoma xenograft model. 
Conclusion: CCT271850 is a potent, selective and orally bioavailable MPS1 kinase 
inhibitor. Based on in vivo pharmacodynamic versus efficacy relationships, we predict that 
more than 80% inhibition of MPS1 activity for at least 24 hours is required to achieve 
tumour stasis or regression by CCT271850. 
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Dividing cells faithfully transmit their genetic information into daughter cells by accurately 
segregating duplicated chromosomes during mitosis. This is ensured by a surveillance 
mechanism called the spindle assembly checkpoint (SAC, also known as mitotic 
checkpoint), which delays mitotic progression until all chromosomes are properly attached 
to spindle microtubules (Foley & Kapoor, 2013; Lara-Gonzalez et al, 2012; Musacchio & 
Salmon, 2007). Inactivation of spindle assembly checkpoint results in premature anaphase 
onset and therefore, missegregation of erroneously attached chromosomes. This 
consequently leads to chromosomal instability and aneuploidy that can either cause cell 
death or tumorigenesis depending on the strength of checkpoint abrogation (Dobles et al, 
2000; Gordon et al, 2012; Kops et al, 2004; Kops et al, 2005). The dual specificity kinase, 
MPS1 (also known as TTK), is one of the core proteins which regulates SAC activation by 
initiating and transducing an inhibitory signal from unattached kinetochores to anaphase 
promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase (Musacchio & Salmon, 
2007). Consequently, APC/C-mediated degradation of the mitotic proteins cyclin B and 
securin, normally required for mitotic exit, is inhibited and cells remain arrested in mitosis 
until all chromosomes are properly attached (Lara-Gonzalez et al, 2012). Incidentally, 
MPS1 kinase activity can also regulate chromosomal attachment and error correction 
(Jelluma et al, 2008b; Maure et al, 2007). Loss of MPS1 activity, therefore, results in both 
abrogation of SAC function and chromosomal misalignment, ultimately leading to severe 
aneuploidy and apoptotic cell death (Hewitt et al, 2010; Jelluma et al, 2008a; Jelluma et al, 
2008b; Kwiatkowski et al, 2010; Santaguida et al, 2010; Schmidt et al, 2005).  
 
A large majority of human cancers are characterised by aneuploidy and chromosomal 
instability, despite normal cells being highly intolerant to both phenotypes (Orr et al, 2015). 
Overexpression of several SAC components, including MPS1 kinase, have been 
suggested as one of the mechanisms through which tumour cells can tolerate high 
aneuploidy and chromosomal instability (Daniel et al, 2011; Yuan et al, 2006). MPS1 is 
overexpressed in various human tumours, including breast, pancreatic, thyroid and 
glioblastoma, and its higher expression levels correlate with poor prognosis in many of 
these tumours (Daniel et al, 2011; Salvatore et al, 2007; Slee et al, 2014; Tannous et al, 
2013). Reduction in MPS1 levels or activity in such tumours can result in loss of cell 
viability (Daniel et al, 2011; Slee et al, 2014), or in increased sensitivity to low doses of 
microtubule polymerising agents such as docetaxel (Maia et al, 2015; Tannous et al, 
2013). Therefore, MPS1 inhibition represents an attractive strategy to target cancers, 
especially those with chromosomal instability (Manchado et al, 2012). Several structurally 
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diverse MPS1 inhibitors have been discovered and undergone preclinical assessments in 
recent times (Liu & Winey, 2012). These include AZ3146 (Hewitt et al, 2010), NMS-P715 
(Colombo et al, 2010), MPI-0479605 (Tardif et al, 2011), CCT251455 (Naud et al, 2013), 
MPS1-IN-3 (Tannous et al, 2013), and compounds from Shionogi (Kusakabe et al, 2015) 
and Bayer (Jemaa et al, 2013).  
 
The availability of robust pharmacodynamic (PD) biomarkers is critical for any modern 
drug development program (Workman, 2003). Inhibition of histone H3 phosphorylation at 
S10, or down-regulation of mitotic proteins such as cyclin B, have been widely used as 
biomarkers for SAC override and the accompanying mitotic exit that results from cellular 
inhibition of MPS1 (Colombo et al, 2010; Kwiatkowski et al, 2010; Naud et al, 2013; Tardif 
et al, 2011). Of several MPS1 inhibitors which have been reported, only a few have 
demonstrated direct MPS1 inhibition in cells using either phospho-specific antibodies for 
the MPS1 T676 autophosphorylation site, or a change in mobility of MPS1 by SDS-PAGE 
(Colombo et al, 2010; Hewitt et al, 2010; Kwiatkowski et al, 2010; Tardif et al, 2011). For 
many inhibitors that have been evaluated in in vivo models, although not exclusively, 
histone H3 phosphorylation at S10 has been the biomarker of choice to demonstrate 
MPS1 inhibition in tumours (Colombo et al, 2010; Jemaa et al, 2013). SAC override and 
consequential reduction in histone H3 phosphorylation at S10 are, however, not specific 
for MPS1 inhibition and can be regulated by other kinases involved in the SAC (Mao et al, 
2003; Santaguida et al, 2011; Saurin et al, 2011).  
 
Our efforts to discover MPS1 inhibitors with favourable biochemical, cellular, 
pharmacokinetic and pharmacodynamic and in vivo properties for a clinical candidate have 
yielded inhibitors from two different chemical series; CCT251455 (Naud et al, 2013) and 
CCT271850 (Innocenti et al, 2016). Here we report an extensive cellular characterisation 
and in vivo parmacodynamic versus efficacy relationship of CCT271850. 
 
Materials and methods: 
 
Cell culture, transfection and proliferation assay 
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Cell lines were obtained from the American Type Culture Collection and grown in their 
recommended culture medium, supplemented with 10% FBS at 37°C in 5% CO2. In-house 
authentication of cell lines by SNP profiling was carried out and cultured cells were 
passaged for less than 6 months before replacement from early passage frozen stocks. 
Cells were regularly screened for Mycoplasma, using a PCR-based assay (VenorGem; 
Minerva Biolabs). Transfections were carried out at approximately 80% confluency with the 
plasmids indicated, using Lipofectamine LTX (15338030, Life Technologies) according to 
the manufacturer's instructions. Cell proliferation assays were carried out by colorimetric 
MTT method (Sigma) as described elsewhere (Mosmann, 1983). Briefly, cells were plated 
in 96-well plates at 2000 to 5000 cells per well (depending on the cell line) followed by 
treatment with two-fold dilutions of 0 to 25 uM drug for 72 hours. Absorbance was 
measured at 570 nm with the Wallac VICTOR2 1420 Multilabel Counter (PerkinElmer). 
 
Immunoprecipitation and immunoblotting 
For immunoprecipitation assay, 1mg of total cell/tumour lysate was incubated with 8 µg of 
pTpS33/37 antibody (44-1325G, Life Technologies) for 1 hour with rotation at 4oC. The 
antibody/protein complexes were captured by further incubation with Protein A sepharose 
beads for 1 hour with rotation at 4oC. Beads were washed three times with completed lysis 
buffer, followed by boiling for 10 min in 2X LDS sample buffer. The samples were used for 
immunoblotting with total MPS1 antibodies as described below. 
For immunoblotting, cells were lysed either in NP-40 alternative (Calbiochem) lysis buffer 
(120 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5, 1% NP-40 supplemented with 
phosphatase and protease inhibitors) or 2X LDS sample buffer (Invitrogen). Equal 
amounts of proteins were resolved by 4% to 12% Bis-Tris NuPAGE gels (Invitrogen), 
transferred to nitrocellulose (Whatman) membranes, and immunoblotted with specific 
antibodies. For gel shift analysis, samples were prepared in SDS-sample buffer and 
resolved by 10% SDS-PAGE.  
 
Immunofluorescence and time-lapse microscopy 
For immunofluorescence, cells were pre-treated with CCT271850 for 1 hour, then treated 
with nocodazole, MG132 and CCT271850 for additional 1 hour. Cells were fixed and 
stained according to the protocol previously described (Gurden et al, 2015). Primary 
antibodies used were: anti-centromere antibodies (ACA) (ImmunoVision, HCT-0100), 
BubR1 (BD Biosciences, 612503), Mad1 (Abcam, ab45286), Mad2 (Bethyl Laboratories 
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Inc., A300-301A), MPS1 (Invitrogen, 35-9100), MPS1 pT33pS37 (Life Technologies, 44-
1325G), Zwint-1 (Abcam, ab84367). Images were acquired using a Zeiss LSM 710 
confocal microscope and processed using Volocity 3D Image analysis software 
(PerkinElmer). Time-lapse microscopy was performed in 96-well Ibidi plate (Thistle 
Scientific) using a Diaphot inverted microscope (Nikon), in a humidified CO2 chamber at 
37°C, using a motorised stage (Prior Scientific), controlled by Simple PCI software 
(Compix). 
 
Flow cytometry 
After treatment with CCT271850 for 24 hours, cells were fixed and stained as described 
previously (Gurden et al, 2015). Briefly, cells were fixed in 70% ethanol, washed in PBS, 
incubated in 10 μg/mL propidium iodide and 0.5% RNase (Sigma) for 30 minutes and 
analysed using LSRII flow cytometer (BD Biosciences). To stain for mitosis, cells were 
incubated for 1 hour at 4°C with anti-MPM2 antibodies (Millipore, 05-368), followed by 1-
hour incubation at 4°C with FITC-conjugated secondary antibodies (Life Technologies). 
 
Meso Scale Discovery (MSD) assay 
MSD assay for detection of autophosphorylation of MPS1 at pT33pS37 sites in cell lysates 
has previously been described (Naud et al, 2013). For MSD from tumours, samples were 
prepared in complete lysis buffer (50 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM 
EGTA, 1% (v/v) Triton X-100, 10 mM NaF, protease inhibitor tablet and phosphatase 
inhibitor cocktails) and 25 - 37.5 µg protein per well was used for the detection of 
phosphorylation at T33/S37. We also measured total MPS1 levels in these tumour 
samples with an MSD assay for GFP which was developed using mouse monoclonal 
MPS1 antibody (Invitrogen, Cat no. 35-9100) as capture antibody and rabbit polyclonal 
GFP antibody (Abcam Cat no. ab290 at 1:2000 dilution) as the detection antibody. Results 
were presented as the ratio of Phospho-MPS1/Total MPS1. 
 
In vivo mouse PK/PD Study 
5 x 106 of MPS1-doxycycline (Dox) inducible DLD-1 human colorectal carcinoma cells 
were injected s.c. bilaterally into the flanks. Once tumours reached a mean diameter of 8-
10 mm animals were put on Dox diet for 3 days and given an oral gavage bolus of Dox 
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(6mg/mouse) 24 hours before dosing of compounds. Animals (n = 3 per group) were 
dosed once daily with CCT271850 (50 mg/kg or 100 mg/kg po) or vehicle (10% DMSO, 
5% Tween 20, 85% saline). Mice were culled at 2, 6, 12 and 24 h after dosing. 
Heparinized plasma was collected and tumours were snap frozen for pharmacokinetics 
(PK) and pharmacodynamics (PD) biomarker analysis. For PK examination, compounds 
were extracted from whole blood, plasma and tissue homogenates with methanol-
containing internal standards using established protocols. CCT271850 concentrations 
were determined using liquid chromatography/tandem mass spectrometry (LC/MS-MS) 
and pharmacokinetics were calculated using Pharsight Phoenix Software (version 6.3). For 
PD examination, samples were lysed and analysed by MSD for pT33pS37and GFP levels 
and ratio of P-MPS1 (pT33pS37)/Total-MPS1 (GFP) in tumour samples at various time 
pointes after 50 mg/kg and 100 mg/kg dosing were calculated. 
 
Efficacy study 
Three million HCT116 human colorectal carcinoma cells were injected s.c. into the right 
flanks of athymic mice. Therapy was initiated when tumours reached a mean diameter of 5 
mm (indicated as day 0). Control mice (n=7) received vehicle (10% DMSO, 5% Tween 20, 
85% saline) and treated mice (n=8) were given CCT271850 at 50mg/kg and 100 mg/kg 
orally twice daily with a break after one week’s dosing. Tumour volumes and body weights 
were measured three times weekly and the study was terminated on day 15 when all 
tumours were excised and weighed. Plasma and tumour samples were collected for 
pharmacokinetic and pharmacodynamic biomarker analysis at 2h and 6h after the final 
dose. 
All animal studies were approved by the local research ethics committee and carried out in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and national guidelines 
(Workman et al, 2010). 
 
Results: 
CCT271850 potently inhibits MPS1 phosphorylation and activity in cells 
CCT271850 (Figure 1A) is a novel and potent small molecule inhibitor of MPS1 kinase 
discovered through our lead optimisation studies on a pyridopyrimidine series of 
compounds (Innocenti et al, 2016; compound 34h). In an in vitro kinase assay, 
CCT271850 inhibited MPS1 activity with IC50 values of 0.0112 ± 0.0046 µM at low ATP (10 
 8 
µM) and 0.02 ± 0.013 M at high ATP (1 mM) concentrations (Table 1). For cellular 
inhibition of MPS1, we evaluated the effect of the inhibitor on MPS1 autophosphorylation 
at the activation site T676, and the N-terminal sites T33/S37 in human colon cancer 
HCT116 cells (Figure 1B). CCT271850 potently inhibited phosphorylation of ectopically 
expressed MPS1 at both sites in a dose-dependent manner (Figure 1B). The decrease in 
phosphorylation was accompanied by corresponding increase in mobility of total MPS1 in 
SDS-PAGE; another measure of the decrease in MPS1 phosphorylation (Figure 1B, lower 
panel).  
 
The N-terminal phosphorylation sites of the MPS1 protein have previously been identified 
as autophosphorylation sites through mass spectrometry of in vitro as well as in vivo 
phosphorylated MPS1 protein (Jelluma et al, 2008; Xu et al, 2009). Here we used 
phospho-MPS1 pThr33/pSer37 antibody (pT33pS37) to demonstrate recombinant MPS1 
is indeed autophosphorylated at these sites in an in vitro kinase assay (Figure S1A). This 
autophosphorylation was previously suggested to be inhibited by the MPS1 inhibitor 
AZ3146 however, it has not been demonstrated (Hewitt et al, 2010). The lack of 
phosphorylation on MPS1 T33A and S37A mutants confirmed the specificity of the 
antibodies (Figure S1C). We were also able to detect phosphorylation of the endogenous 
MPS1 T33S37 in immunoprecipitation assays following nocodazole-mediated mitotic 
arrest of HCT116 cells and treatment with CCT271850 in the present of the proteasome 
inhibitor MG132 to block mitotic abrogation (Figure 1C), as well as when using the 
previously reported MPS1 inhibitor, CCT251455 (Naud et al, 2013) (Figure S1B). MPS1 
phosphorylation was strongly induced upon nocodazole-mediated mitotic arrest and was 
completely inhibited by treatment of arrested cells with CCT271850. In addition, 
phosphorylation of the endogenous MPS1 at T33/S37 sites in mitotic cells and its inhibition 
by CCT271850 were demonstrated by immunofluorescence using pT33pS37 antibodies 
(Figure 1D). pT33pS37 staining was co-localized with anti-centromere antibodies (ACA) at 
kinetochores, but was completely lost upon treatment with CCT271850. To quantitatively 
measure MPS1 autophosphorylation in cells at the T33/S37 sites, we optimised an 
electrochemiluminescence (Meso Scale Discovery, MSD) assay (Naud et al, 2013). Using 
this approach we showed that CCT271850 potently inhibited MPS1 T33/S37 
phosphorylation with IC50 value of 0.059 ± 0.022 µM (Table 1). Furthermore, we showed 
that treatment of nocodazole-arrested HCT116 cells with CCT271850 caused SAC 
abrogation as measured by inhibition of the histone H3 phosphorylation at S10 with an IC50 
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value of 0.067 ± 0.004 µM (Table 1). Moreover, when compared side-by-side with NMS-
P715, CCT271850 was ~8-fold more potent (Figure S1D). 
 
Effects of CCT271850 on the activation of spindle assembly checkpoint and the cell 
cycle 
The SAC ensures accurate chromosomal segregation by delaying the onset of anaphase 
until all chromosome are properly attached to the spindle poles (Lara-Gonzalez et al, 
2012). MPS1 activity is required for activation of the SAC (Kang et al, 2007) and inhibition 
of its activity results in SAC override and missegregation of chromosomes (Colombo et al, 
2010; Tardif et al, 2011). HeLa cells treated with CCT271850, showed an early exit from 
mitosis (Figure 2A). Cells treated with 0.3 µM of CCT271850 spent, on average, 12 
minutes to pass from nuclear envelope breakdown to the onset of anaphase, compared to 
57 minutes for the untreated control cells (Figure 2A). The observed SAC abrogation 
resulted in a large percentage of cells undergoing cell division with unaligned 
chromosomes, resulting in aneuploidy and a loss of cell cycle profiles by flow cytometry 
(Figures 2B and 2C). It is known that MPS1 activity is required for recruitment of spindle 
checkpoint proteins to kinetochores (London & Biggins, 2014). We therefore tested the 
recruitment of Mad1, Mad2 and BubR1 to the unattached kinetochores (Hewitt et al, 2010; 
Sliedrecht et al, 2010) after treatment of HeLa cells with CCT271850. The results showed 
that Mad1, Mad2 and BubR1 levels were abolished at the unattached kinetochores (Figure 
2D, 2E and S2A), whereas Zwint-1 levels remain unchanged (Figure S2B). 
 
MPS1 inhibition by CCT271850 sensitises selectively MSI+ colon cancer and basal 
breast cancer cell lines to cell death  
We further investigated the cellular effect of CCT271850 on asynchronous HCT116 cells. 
Cells were treated with different concentrations of CCT271850 for 24, 48 and 72 hours and 
inhibition of histone H3 phosphorylation and PARP cleavage was examined by 
immunoblotting. As shown in Figure 3A, histone H3 phosphorylation at S10 was 
increasingly inhibited in a time-dependent manner by all three concentrations of the 
compound. Induction of apoptotic cell death upon CCT271850 treatment also increased in 
a time-dependent manner as determined by the levels of cleaved PARP. A marked 
increase on p53 levels in HCT116 cells upon treatment with CCT271850 for 24 and 48 
hours is consistent with induced p53 response due to aneuploidy (Tardif et al, 2011). 
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Treatment with CCT271850 for 24 and 48 hours also resulted in a reduction of MPS1 
protein levels, indicating mitotic exit (Cui et al, 2010).  
 
We have recently generated HCT116 and DLD1 cell lines resistant to a variety of MPS1 
inhibitors due to specific point mutations in MPS1 kinase domain (Gurden et al, 2015). To 
determine whether the cellular effects seen upon CCT271850 treatment in Figure 3A were 
selectively caused by MPS1 inhibition (Figure 3A), we used the AZR1-resistant HCT116 
cells carrying the MPS1 S611G mutation, as a model. As shown in Figure 3B, inhibition of 
histone H3 phosphorylation by CCT271850 in AZR1 cells was abolished compared with 
the parental HCT116 cells. Similarly, PARP cleavage upon CCT271850 treatment was 
significantly reduced in AZR1 cell line, indicating that the apoptotic cell death induced by 
CCT271850 is mediated by MPS1 inhibition. Inhibition of P-histone H3 and PARP 
cleavage by CCT271850 in AZR1 cell lines was seen only at higher concentrations of 
CCT271850 (≥1 M) (Figure 3B and S3). 
 
To evaluate CCT271850 anti-proliferation effects in a large panel of human cancer cell 
lines, 91 cell lines were treated for 72 hours and 14 days at different compound 
concentrations in growth inhibition assays. The growth inhibition values as measured by 
IC50, are summarised in Table 2 and Table S1. In summary, at 72 hours of CCT271850 
treatment, more than half the cell lines (57/91) showed IC50 values below the average of 
1.588 µM, and nearly half (45/91) showed an IC50 at submicromolar values. Cell lines from 
colon and head and neck cancers were among the most sensitive. Importantly, 
microsatellite instability-positive (MSI+) colon cancer cell lines were more sensitive to cell 
death by CCT271850 in comparison to microsatellite stable (MSS) cell lines (average IC50 
at 72 hours: MSI+ = 0.276 ± 0.06, MSS = 1.31 ± 0.06; p = 0.03; Table 2). In addition, in a 
panel of 20 breast cancer cell lines, we found that the basal, as well as specifically the 
PTEN-deficient basal cancer cells, were more sensitive to cell death by CCT271850 in 
comparison to luminal breast cancer cell lines (average IC50 at 96 hours: Basal = 0.7 ± 0.2, 
Luminal = 2.1 ± 0.54; p = 0.014; Table 2).  
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Development of PD biomarker assay for measuring direct inhibition of MPS1 in 
xenograft tumours 
The indirect readout of the inhibition of histone H3 phosphorylation at S10 has been widely 
used as a biomarker for inhibition of MPS1 (Colombo et al, 2010; Kwiatkowski et al, 2010; 
Santaguida et al, 2010; Tardif et al, 2011). Mitotic exit following MPS1 inhibition leads to a 
robust reduction in histone H3 phosphorylation. Similar modulation of other mitotic markers 
such as cyclin B levels has also been shown in response to MPS1 inhibition (Colombo et 
al, 2010; Tardif et al, 2011). Although direct inhibition of MPS1 autophosphorylation using 
phospho-specific antibodies has been reported in cells (Sliedrecht et al, 2010; Tardif et al, 
2011), such inhibition has never been demonstrated in ex-vivo tumour samples. In 
addition, although a direct inhibition of phosphorylation of the natural substrate of MPS1, 
KNL1, by MPS1 inhibitors has been described using immunohistochemistry (Maia et al, 
2015), this method it is not as quantitative as an Elisa-type method such as MSD assay. 
To directly measure MPS1 inhibition using CCT271850 in a quantitative method we have 
recently generated stable DLD1 cell line clones where GFP-MPS1 is overexpressed in a 
doxycycline-inducible manner (Gurden et al, 2015). To measure autophosphorylation of 
MPS1 in vivo, we subcutaneously injected DLD1-GFP-MPS1 cells into mice to establish 
xenograft tumours that express ectopic MPS1 upon induction by doxycycline. Despite the 
levels of GFP-MPS1 being only 1.5-fold higher compared to endogenous MPS1 (band 
intensity of GFP-MPS1 versus endogenous MPS1; Figure 4A), the signal for MPS1 
autophosphorylation at T33/S37 in MSD assay was robustly increased in DOX-induced 
tumours, compared to the non-induced tumours (Figure 4B). The expression of GFP-
MPS1 in these tumour samples was also confirmed by the MSD assay in a PK/PD study 
conducted with CCT271850 compound in the inducible DLD1 xenograft tumour (Figure 
4C). Importantly, at 2, 6 and 12 hours after a single dose of 100mg/kg of CCT271850, 
there was >90% inhibition of MPS1 auto-phosphorylation, which dropped to 79% at 24 
hours (Figure 4D). When a single dose of 50mg/kg of CCT271850 was used, the inhibition 
ranged from ~89% at 2 and 6 hours, to 61% at 24 hours after treatment. At 12 hours, 50 
and 100mg/kg dosing of inhibitor caused 90% and 78% reduction in MPS1 
phosphorylation respectively. When analysing the tumour compound concentration, we 
found that concentration of CCT271850 in the tumours was >1 µM at all time points, which 
is significantly higher than the IC50 value of CCT271850 in DLD1 cells (396 nM; Figure 
4E). The plasma concentration of CCT271850 was comparable at 2 and 6 hours time 
points but gradually decreased at 12 and 24 hours (Figure 4F). The greatest drop in 
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inhibition of MPS1 phosphorylation was observed for 50mg/kg at 24 hours, which 
correlated with the lowest levels of the compound in both plasma and tumour. Similar 
results were obtained when 100mg/kg of CCT251455, our first published MPS1 inhibitor 
(Naud et al, 2013), were dosed in mice bearing DOX-induced DLD1 xenografts. 
Autophosphorylation of MPS1 at the T33/S37 sites were completely inhibited in tumours 
collected at 2 and 6 hours after treatment, whereas the levels of MPS1 overexpression 
(GFP) measured by MSD assays were similar in all treated and control samples (Figure 
S4).  
 
Efficacy of CCT271850 in HCT116 xenografts 
We then examined the efficacy of CCT271850 in vivo using HCT116 tumour xenografts. 
Mice bearing tumour xenografts were dosed twice daily with 50mg/kg or 100 mg/kg of 
CCT271850 for days 0-7 and 12-15. Moderate level of efficacy at the dose of 100mg/kg 
was achieved with tumour versus control (T/C) of 60% based on the final tumour volume 
(Figure 5A). Treatment with CCT271850 was well tolerated in both rounds of dosing with 
less than 8% body weight loss compared with the vehicle-treated controls over 15 days 
(Figure 5B). Whilst this T/C is still modest, it has been shown in the literature that only 
moderate efficacy can be achieved in mice models with tolerated doses of MPS1 inhibitors 
as single agent in the models that have been tested (Colombo et al, 2010; Kusakabe et al, 
2015; Laufer et al, 2014; Tardif et al, 2011, Maia et al, 2015), indicating that combination 
studies with standard-of-care may lead to a more successful use of MPS1 inhibitors in 
clinic in this particular type of cancer. 
 
Discussion 
 
Mitosis has attracted a large number of studies focusing on cancer for decades; either to 
identify mitotic mechanisms involved in cancer, or at a translational level, to target fast 
proliferating cancer cells using anti-mitotic drugs. There is no doubt that anti-mitotics are a 
success in certain types of cancer, but the lack of differentiation between normal and 
cancer cells underlines their limitations in clinic. Mitotic kinases have been identified as 
essential proteins in regulating mitosis and therefore they have represented an attractive 
target in cancer therapy during the past two decades.  
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MPS1 is an essential kinase in initiating the spindle assembly checkpoint, which, in 
cooperation with Aurora-B kinase that predominantly maintains SAC signalling (Gurden et 
al, 2016), represents the cornerstone of this surveillance mechanism. MPS1 has been 
found to be deregulated in a variety of human cancers and has been associated with 
certain genetic abnormalities characterised in tumour cells, including chromosomal 
instability (Carter et al, 2006) and aneuploidy (Brough et al, 2011; Gordon et al, 
2012). RNAi-mediated knockdown or chemical inhibition of MPS1 has also been shown to 
mediate cell death in PTEN-deficient breast tumour cells (Brough et al, 2011). Therefore, 
MPS1 has been brought to the attention as an anticancer target.  
Here we present the discovery of CCT271850, a novel, oral, potent and selective MPS1 
inhibitor in biochemical and cellular assays, with in vivo activity. CCT271850-induced 
growth inhibition was observed in a wide range of cancer cell lines. The highest sensitivity 
was observed in colon cancer cell lines, particularly the MSI-positive colon cancer cell 
lines in comparison to MSS. In addition, basal breast cancer cell lines, some of which are 
also PTEN-deficient, showed higher sensitivity to cell death upon MPS1 inhibition in 
comparison to luminal breast cancers, indicating a potential patient stratification for 
treatment with an MPS1 inhibitor. Consistent with MPS1 inhibition, CCT271850-treated 
cells lost kinetochore localisation of the checkpoint proteins BUBR1, MAD1 and MAD2, 
spent less time in mitosis compared to untreated cells, underwent an abnormal division 
with unaligned chromosomes, which caused aneuploidy and cell death. We have 
previously shown that following MPS1 inhibition, the majority of the cells die after one or 
two mitoses (Gurden et al, 2016), indicating a distinct difference between MPS1 inhibitors 
in comparison to other mitotic kinase inhibitors such as Aurora and Polo-like kinase 
inhibitors; these inhibitors require multiple cell cycles to induce cell killing, thus have a 
narrower therapeutic window in clinic (Bavetsias, Linardopoulos, 2015). These effects of 
CCT2571850 were specifically caused through MPS1 since cell lines, previously 
generated (Gurden et al, 2015), containing a S611G mutation in MPS1 were resistant to 
inhibition.  
The lack of a direct, quantitative biomarker for MPS1 inhibition in order to identify a 
pharmacodynamic versus efficacy relationship, prompted us to set up and optimise an 
inducible MPS1 model in DLD1 colon cancer cells, in order to directly measure MPS1 
inhibition via MPS1 auto-phosphorylation. Assays using MSD have been proved to be very 
sensitive and quantitative in vitro and in vivo. We validated and characterised the 
specificity of a commercially available T33/S37 anti-MPS1 phospho-antibody, which we 
used to analyse MPS1 activity in biochemical assays, in cell and in vivo. We showed that 
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100 mg/kg of CCT271850 is sufficient to inhibit MPS1, in vivo, for at least 24 hrs in 
HCT116 human tumour xenografts, by approximately 80%, as shown by a decrease in 
MPS1 autophosphorylation levels. This level of inhibition resulted in a moderate effect on 
tumour growth, suggesting that higher, more sustained target inhibition may be required 
for a more robust tumour response. Likewise, although 50 mg/kg showed robust target 
inhibition for up to 12 hours, this was insufficient to produce any reduction in tumour 
volume. However, since higher dosing regiments are limited by animal toxicity, a single 
agent administration may not be as efficacious as is required in clinical settings in the type 
of cancer models tested. This suggests that changing direction towards using MPS1 
inhibitors in combination with standard-of-care drugs, for example with taxanes, may be a 
more beneficial approach for the clinic. It has been recently shown that paclitaxel induces 
multipolar spindles and mitotic delay (Zasadil et al, 2014). Our hypothesis is that MPS1 
inhibition will induce abrogation of paclitaxel-induced mitotic delay causing gross 
chromosomal abnormalities and massive cell death in cancer cells. 
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Titles and legends to figures: 
 
Figure 1. CCT271850 inhibits MPS1 autophosphorylation in cells. A. Structure of 
CCT271850. B. HCT116 cells transiently expressing Myc-tagged MPS1 were treated with 
increasing concentrations of CCT271850 for 2 hours. Cell lysates were analysed for MPS1 
autophosphorylation (at pT33pS37 and pT676 sites) and gel shift using immunoblotting. C. 
HCT116 cells were synchronised with nocodazole for 24 hours followed by treatment with 
indicated concentrations of CCT271850 for 2 hours in the presence of MG132. Cell lysates 
were immunoprecipitated for endogenous MPS1 with phospho-specific anti-pT33pS37 
antibodies and immunoblotted with anti-MPS1 antibodies. Total cell lysates were also 
immunoblotted with anti-MPS1 antibodies as a control for immunoprecipitation input (lower 
panel). D. Immunofluorescence for MPS1 pT33pS37 localization at kinetochores with and 
without treatment with CCT271850. Cells were treated with CCT271850 for 1 hour, 
followed by treatment with nocodazole, MG132 and CCT271850 for an additional hour. 
Cells were fixed and stained as indicated. 
 
Figure 2. Mitotic defects in cells treated with CCT271850. A. Time from nuclear envelope 
breakdown to anaphase onset in asynchronous HeLa cells stably expressing Histone H2B-
mCherry was measured using time-lapse microscopy in the presence or absence of 0.3 
µM of CCT271850. Images were taken every 3 minutes for 24 hours. B. Quantification of 
mitotic defects of HeLa cells, from A. C. Cell cycle analysis of HCT116 cells treated with 
the indicated concentrations of CCT271850 for 24 hours. D and E. Immunofluorescence 
for Mad1 and Mad2 localization at kinetochores with and without treatment with 
CCT271850. Cells were treated with CCT271850 for 1 hour, followed by treatment with 
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nocodazole, MG132 and CCT271850 for an additional hour. Cells were fixed and stained 
as indicated.  
 
Figure 3. Biomarker modulation and anti-proliferative effects of CCT271850. A. Time 
course of biomarker modulation by CCT271850 in HCT116 cells. Cells were treated with 
indicated concentrations of the inhibitor for 24, 48 and 72 hours. Cell lysates were 
analysed by immunoblotting for inhibition of histone H3 phosphorylation at S10, induction 
of p53 and PARP cleavage. Total histone H3 and alpha-tubulin were used as loading 
controls. B. Biomarker modulation by CCT271850 is reversed in AZR1 cell line expressing 
an inhibitor-resistant mutant of MPS1. HCT116 WT and AZR1 resistant cell lines were 
treated with indicated concentrations of CCT271850 for 48 hours and analysed for 
inhibition of histone H3 and PARP cleavage as described above.  
 
Figure 4. Development of a PD biomarker assay for measuring direct inhibition of MPS1 in 
DLD1 GFP-MPS1 Dox inducible xenografts. A. Five million DLD1 cells, stably expressing 
Dox-inducible GFP-MPS1 were used to grow tumours in athymic mice. Mice were dosed 
with ~6 mg of doxycycline (Dox) per day for 3 days. Tumours were lysed and equal 
amount of protein was used for immunoblotting with GFP and MPS1 antibodies. B. MSD 
assay for detection of MPS1 phosphorylation in xenograft tumours. 37.5 µg and 50 µg of 
cell lysates from non-induced and induced tumours were used for MSD assay with 
pTpS33/37 antibodies. C. Two concentrations (12.5 µg and 25 µg) of cell lysates were also 
used for MSD with GFP antibodies. D. PK/PD studies in DLD1 GFP-MPS1 Dox inducible 
xenografts treated with CCT271850. Mice bearing bilateral DLD1 (GFP-MPS1 Dox 
inducible) xenografts were placed on Dox diet for 3 days (~6 mg/day). 24h prior to harvest, 
mice were given a single 10mg oral gavage bolus of Dox, followed by a single dose of 50 
mg/kg or 100 mg/kg of CCT271850. Tumours and plasma samples were collected at 2, 6, 
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12 and 24h after CCT271850 dosing and followed with PK and PD examination. Samples 
were lysed and analysed by MSD for pTpS33/37 and GFP. Ratio of phospho-MPS1 
(pTpS33/37)/Total-MPS1 (GFP) in tumour samples at various time pointes after 50 mg/kg 
and 100 mg/kg CCT271850 dosing was calculated. Concentration of CCT271850 in 
tumours (E) and plasma (F) was measured. 
 
Figure 5. Efficacy of CCT271850 in HCT116 xenografts. Athymic mice bearing HCT116 
tumours were dosed with vehicle, 50 mg/kg or 100 mg/kg of CCT271850 orally twice daily 
(b.i.d) with a break after one week’s dosing for days 0-7 and 12-15. A. Mean tumour 
volumes ± S.E.M. for control and CCT271850 treated mice were measured at different 
days throughout the experiment. B. Body weights for treated and control mice were 
measured.  
 
Supplementary figure legends: 
Figure S1. Inhibition of MPS1 autophosphorylation in vitro and in vivo. A. In vitro 
phosphorylation of MPS1 at T33/S37 sites. Recombinant GST-MPS1 was incubated at 
30oC for 30 minutes in kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 0.5 mM DTT and 
10 µM ATP) with or without AZ3146. Proteins were resolved by SDS-PAGE and 
immunoblotting was carried out using pTpS33/37 antibodies and total MPS1 antibodies. B. 
Phosphorylation of endogenous MPS1 at T33/S37 sites. HCT116 cells were synchronized 
in mitosis with overnight nocodazole treatment followed by 2h treatment with an MPS1 
inhibitor, CCT251455. Cell lysates were immunoprecipitated with MPS1 antibody and 
probed with anti-pTpS33/37 antibody. Blots were stripped and re-probed with anti-MPS1 
antibody for loading control. C. HCT116 cells were transfected with MPS1 wild-type and 
T33A/S37A mutants, treated overnight with nocodazole and were treated with CCT251455 
for additional 2 hours to show inhibition of MPS1 at T33/S37 and T676 by immunoblotting, 
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as well as band shift of Myc-MPS1 in the same blot. D. Inhibition of histone H3 
phosphorylation at S10 by CCT271850 and NMS-P715. HCT116 cells were treated with 
indicated concentrations of both inhibitors for 2 hours. Cells were lysed and analysed for 
histone H3 phosphorylation by immunoblotting. Alpha tubulin was used as loading control.  
 
Figure S2. Effect of CCT271850 treatment on (A) BubR1 and (B) Zwint-1 localization. 
HeLa cells were fixed and stained with indicated antibodies as described in materials and 
methods. 
 
Figure S3. Inhibition of phosphorylation on MPS1 wild-type and S611G mutants by 
CCT271850. HCT116 cells were transfected with MPS1 wild-type and S611G mutant 
plasmids and were treated with a range of 0 - 2.5 µM of CCT271850 for 2 hours. MPS1 
phosphorylation was analysed by immunoblotting using pTpS33/37 and pT676 antibodies. 
Tubulin was used as loading control.  
 
Figure S4. PK/PD studies in DLD1 xenografts with MPS1 inhibitor CCT251455. Mice 
bearing bilateral DLD1 (GFP-MPS1 Dox inducible) xenografts were placed on doxycycline 
(Dox) diet for 3 days (~6 mg/day). 24h prior to harvest, mice were given a single 10 mg 
oral gavage bolus of Dox, followed by a single dose of 100 mg/kg of CCT251455. Tumours 
were collected 2h and 6h after CCT251455 dosing for PD examination. Samples were 
lysed and 50 µg/well cell lysates were used for MSD with pTpS33/37 (left) and 10 µg/well of 
cell lysates were used for MSD with GFP antibodies (right). 
